Loading...
XKRX
092730
Market cap98mUSD
Jul 09, Last price  
18,920.00KRW
1D
-3.12%
1Q
10.19%
Jan 2017
-27.51%
IPO
154.09%
Name

NeoPharm Co Ltd

Chart & Performance

D1W1MN
XKRX:092730 chart
P/E
5.30
P/S
1.12
EPS
3,568.13
Div Yield, %
3.17%
Shrs. gr., 5y
14.63%
Rev. gr., 5y
10.12%
Revenues
132.18b
+11.07%
11,453,997,0005,766,635,00012,477,163,00014,608,873,00014,661,158,00016,944,305,40018,774,371,84620,137,820,92025,602,822,44035,964,569,60242,368,623,34253,633,506,62866,274,581,62383,240,333,00081,625,348,00087,930,720,00085,033,138,00097,104,890,000119,013,744,000132,184,000,000
Net income
27.91b
+20.99%
3,507,594,0001,797,205,0003,285,857,0002,054,958,0001,290,017,000904,242,300647,762,9271,895,049,5302,568,482,3303,407,145,1377,742,493,66911,559,211,33715,369,685,34919,245,382,00018,130,855,00017,713,276,00017,027,040,00023,212,796,00023,064,752,00027,905,000,000
CFO
28.41b
+52.49%
2,521,991,0001,195,643,0004,575,440,0001,819,222,000-114,716,0003,932,955,980564,344,7002,371,250,6806,848,448,9606,094,692,9139,156,579,73410,646,058,48216,179,233,44419,223,990,00017,073,759,98821,681,190,19818,160,509,70723,262,730,18018,630,797,00028,409,737,000
Dividend
Dec 29, 2025600 KRW/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

Established on July 1, 2000, NeoPharm Co., Ltd. is a Daejeon, South Korea-based company that develops, produces, and markets a diverse range of cosmetic, medical, and health products. Its offerings notably include advanced skincare formulations, both emulsified and functional, designed to address issues such as sensitive and dry skin, as well as to provide treatment for atopic dermatitis, psoriasis, and the adverse effects associated with steroid use.
URL
https://neopharm.co.kr/ko/default.do
IPO date
Jan 30, 2007
Employees
Domiciled in
KR
Incorporated in
KR

Valuation

Title
KRW in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT